A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

Retrovirology

Volumn 9, Issue , 2012, Pages

  Johnson, Barry C ^a   Pauly, Gary T ^a   Rai, Ganesha ^b   Patel, Disha ^c   Bauman, Joseph D ^c   Baker, Heather L ^b   Das, Kalyan ^c   Schneider, Joel P ^a   Maloney, David J ^b   Arnold, Eddy ^c   Thomas, Craig J ^b   Hughes, Stephen H ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

HIV; Reverse transcriptase; Rilpivirine

Indexed keywords

DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROPHOBICITY; STRUCTURE ACTIVITY RELATION; VIRUS INFECTIVITY; X RAY CRYSTALLOGRAPHY;

CELL LINE; CRYSTALLOGRAPHY; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870379961     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-99     Document Type: Article

References (32)

1. HIV/AIDS http://www.who.int/topics/hiv_aids/en/.
2. Hartman TL, Buckheit RW. The continuing evolution of HIV-1 therapy: identification and development of novel antiretroviral agents targeting viral and cellular targets. Mol Biol Int 2012, 2012:401965. 3400388, 22848825.
3. Li D, Zhan P, De Clercq E, Liu X. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem 2012, 55:3595-3613. 10.1021/jm200990c, 22268494.
4. Jorgensen WL, Bollini M, Thakur VV, Domaoal RA, Spasov KA, Anderson KS. Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc 2011, 133:15686-15696. 10.1021/ja2058583, 3183387, 21853995.
5. Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, et al. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 2008, 51:5000-5008. 10.1021/jm8004493, 18665583.
6. Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, et al. Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses. J Med Chem 2009, 52:7163-7169. 10.1021/jm901230r, 19883100.
7. Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, et al. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J Med Chem 2008, 51:7449-7458. 10.1021/jm800527x, 19007201.
8. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010, 44:157-165. 10.1345/aph.1M359, 19996323.
9. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005, 48:1689-1696. 10.1021/jm040127p, 15771411.
10. Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004, 47:2550-2560. 10.1021/jm030558s, 15115397.
11. Das K, Bauman JD, Clark AD, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008, 105:1466-1471. 10.1073/pnas.0711209105, 2234167, 18230722.
12. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010, 54:718-727. 10.1128/AAC.00986-09, 2812151, 19933797.
13. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012, 59:39-46. 10.1097/QAI.0b013e31823df4da, 22067667.
14. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237. 10.1016/S0140-6736(11)60983-5, 21763935.
15. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011, 85:11300-11308. 10.1128/JVI.05584-11, 3194954, 21849444.
16. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:39-48. 10.1016/S0140-6736(07)61048-4, 17617271.
17. Chen X, Zhan P, Li D, De Clercq E, Liu X. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem 2011, 18:359-376.
18. Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005, 48:2072-2079. 10.1021/jm040838n, 15771449.
19. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005, 48:1901-1909. 10.1021/jm040840e, 15771434.
20. Liang YH, Feng XQ, Zeng ZS, Chen FE, Balzarini J, Pannecouque C, De Clercq E. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. ChemMedChem 2009, 4:1537-1545. 10.1002/cmdc.200900212, 19591191.
21. Sun LQ, Zhu L, Qian K, Qin B, Huang L, Chen CH, Lee KH, Xie L. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 Non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem 2012, 55:7219-7229. 10.1021/jm3007678, 22856541.
22. Das K, Bauman JD, Rim AS, Dharia C, Clark AD, Camarasa MJ, Balzarini J, Arnold E. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 2011, 54:2727-2737. 10.1021/jm101536x, 3361896, 21446702.
23. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, Stuart DI. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 1997, 94:3984-3989. 10.1073/pnas.94.8.3984, 20554, 9108091.
24. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012, 60:33-42. 10.1097/QAI.0b013e31824d006e, 22343174.
25. Kelley JL, Linn JA, Krochmal MP, Selway JW. 9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity. J Med Chem 1988, 31:2001-2004. 10.1021/jm00118a025, 2845083.
26. Wolfe JP, Buchwald SL. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides. J Org Chem 2000, 65:1144-1157. 10.1021/jo9916986, 10814066.
27. Guillemont JEG, Paugam M, Delest BFM, Heeres J, Lewi PJ, Janssen PAJ, . Arts FJJH HIV inhibiting bicyclic pyrimidine derivatives 2008, USA: Office USPaT ed, Arts FJJH.
28. Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH. 4′-C-methyl-2′-deoxyadenosine and 4′-C-ethyl-2′-deoxyadenosine inhibit HIV-1 replication. Antimicrob Agents Chemother 2011, 55:2379-2389. 10.1128/AAC.01290-10, 3088259, 21343443.
29. Bauman JD, Das K, Ho WC, Baweja M, Himmel DM, Clark AD, Oren DA, Boyer PL, Hughes SH, Shatkin AJ, Arnold E. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res 2008, 36:5083-5092. 10.1093/nar/gkn464, 2528191, 18676450.
30. Otwinowski Z, Minor W. Crystallography of biological macromolecules 2001, Boston: Kluwer Academic Publishers.
31. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66:213-221. 10.1107/S0907444909052925, 2815670, 20124702.
32. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60:2126-2132. 10.1107/S0907444904019158, 15572765.